Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21036024 | 0.87 | AGBL2 (0.36) | AGBL2L3MBTL1ALDH1A1HPGDMEN1 | |
| SCHEMBL13848696 | 0.82 | NOS3 (0.37) | AGBL2ALDH1A1NPSR1POLBNOS3 | |
| SCHEMBL28658726 | 0.79 | NPSR1 (0.43) | AGBL2L3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29851143 | 0.79 | NPSR1 (0.43) | AGBL2L3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24675316 | 0.79 | AGBL2 (0.46) | AGBL2L3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL24177929 | 0.78 | AGBL2 (0.41) | AGBL2L3MBTL1ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL31018138 | 0.77 | AGBL2 (0.50) | AGBL2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2084458 | 0.77 | AGBL2 (0.50) | AGBL2ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9886104 | 0.77 | LMNA (0.43) | AGBL2ALDH1A1HPGDSMN1; SMN2KMT2A | |
| SCHEMBL17778214 | 0.77 | AGBL2 (0.47) | AGBL2L3MBTL1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555106-B1 | BICYCLIC THIAZINE AND OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | AGBL2 4820/4885L3MBTL1 3424/4885ALDH1A1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.